Report Overview

The Indian Antibiotics Drug market size stood at around USD 120 billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of 12% during the forecast period.

The burden of infectious diseases in India is among one of the highest in the world. The Million Death Study reported that diseases of infectious origin such as pneumonia and diarrhoea accounted for 50% (067 million of 134 million) of all deaths in children aged 159 months in India. The burden of infectious diseases in India is also reflected in both value and volume of antibiotic sales in the country and the size of the antibiotic market as proportion of total pharmaceutical market. India's excessive antibiotic usage was now leading to a powerful never-before-seen mutation within bacteria. Antibiotic use in India has risen sharply, with about a 30% increase in their per capita.



Market Drivers

The rising prevalence of infectious diseases and supportive government legislation are the major drivers of the market. Moreover, an increase in antibiotic resistance infections due to misuse or overuse of antibiotics is expected to shift the prescription patterns to novel therapies to treat bacterial infection.Increasing disease burden is compelling government and non-government bodies to invest in R&D initiatives and boost the development of novel antibiotics and supportive regulatory policies to expedite the approval process and research funding. Pharmaceutical companies are collaborating for the development of new therapies to reduce the cost burden of the drug development process. An increasing number of public-private collaborations, wherein funding and innovative R&D approaches are provided by public agencies to firms developing antibiotics, is expected to boost the product pipeline.